An interventional study of Cabergoline in Diabetes Type 2, sponsored by Mashhad University of Medical Sciences. Status unknown. Per ClinicalTrials.gov, last updated 2011-10-25.
Sponsored by Mashhad University of Medical Sciences · Not applicable, Interventional, and Treatment
Diabetic patients with poorly control blood sugar are prescribed cabergoline for 1 months and their blood glucose is evaluated.
9,359 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,318 are open to participants now.
This study's planned enrollment of 10 is below the median of 80 across 7,525 interventional studies indexed under Diabetes Mellitus, Type 2.
Browse Diabetes Mellitus, Type 2 studies →Mashhad University of Medical Sciences is the lead sponsor of 90 studies on the registry; 3 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
0,5mg per week
Also known as: Dastinex
FBS (fasting blood sugar)
Time frame: 30days
HbA1C
Time frame: 30days
No study locations are listed for this record.
This study is status unknown, as verified in Oct 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Mashhad University of Medical Sciences